BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $1.96 billion. The enterprise value is $2.49 billion.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, before market open.
Earnings Date | Aug 4, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BCRX has 209.25 million shares outstanding. The number of shares has increased by 5.50% in one year.
Current Share Class | 209.25M |
Shares Outstanding | 209.25M |
Shares Change (YoY) | +5.50% |
Shares Change (QoQ) | +3.80% |
Owned by Insiders (%) | 1.07% |
Owned by Institutions (%) | 85.20% |
Float | 207.02M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 36.65 |
PS Ratio | 3.86 |
Forward PS | 3.03 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 4.95 |
EV / EBITDA | 66.52 |
EV / EBIT | 72.39 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93
Current Ratio | 2.93 |
Quick Ratio | 2.78 |
Debt / Equity | n/a |
Debt / EBITDA | 20.87 |
Debt / FCF | n/a |
Interest Coverage | 0.35 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | 4.54% |
Return on Invested Capital (ROIC) | 5.71% |
Return on Capital Employed (ROCE) | 10.12% |
Revenue Per Employee | $868,078 |
Profits Per Employee | -$92,190 |
Employee Count | 580 |
Asset Turnover | 1.06 |
Inventory Turnover | 9.82 |
Taxes
In the past 12 months, BCRX has paid $2.29 million in taxes.
Income Tax | 2.29M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +51.46% in the last 52 weeks. The beta is 1.10, so BCRX's price volatility has been higher than the market average.
Beta (5Y) | 1.10 |
52-Week Price Change | +51.46% |
50-Day Moving Average | 9.84 |
200-Day Moving Average | 8.28 |
Relative Strength Index (RSI) | 34.21 |
Average Volume (20 Days) | 3,632,036 |
Short Selling Information
The latest short interest is 23.08 million, so 11.03% of the outstanding shares have been sold short.
Short Interest | 23.08M |
Short Previous Month | 24.02M |
Short % of Shares Out | 11.03% |
Short % of Float | 11.15% |
Short Ratio (days to cover) | 5.52 |
Income Statement
In the last 12 months, BCRX had revenue of $503.49 million and -$53.47 million in losses. Loss per share was -$0.26.
Revenue | 503.49M |
Gross Profit | 323.48M |
Operating Income | 34.44M |
Pretax Income | -146.50M |
Net Income | -53.47M |
EBITDA | 37.47M |
EBIT | 34.44M |
Loss Per Share | -$0.26 |
Full Income Statement Balance Sheet
The company has $295.09 million in cash and $829.29 million in debt, giving a net cash position of -$534.20 million or -$2.55 per share.
Cash & Cash Equivalents | 295.09M |
Total Debt | 829.29M |
Net Cash | -534.20M |
Net Cash Per Share | -$2.55 |
Equity (Book Value) | -451.93M |
Book Value Per Share | -2.16 |
Working Capital | 270.12M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$25.85 million and capital expenditures -$1.03 million, giving a free cash flow of -$26.89 million.
Operating Cash Flow | -25.85M |
Capital Expenditures | -1.03M |
Free Cash Flow | -26.89M |
FCF Per Share | -$0.13 |
Full Cash Flow Statement Margins
Gross margin is 64.25%, with operating and profit margins of 6.84% and -10.62%.
Gross Margin | 64.25% |
Operating Margin | 6.84% |
Pretax Margin | -10.17% |
Profit Margin | -10.62% |
EBITDA Margin | 7.44% |
EBIT Margin | 6.84% |
FCF Margin | n/a |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -5.50% |
Shareholder Yield | -5.50% |
Earnings Yield | -2.73% |
FCF Yield | -1.37% |
Dividend Details Analyst Forecast
The average price target for BCRX is $16.75, which is 78.95% higher than the current price. The consensus rating is "Buy".
Price Target | $16.75 |
Price Target Difference | 78.95% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Revenue Growth Forecast (5Y) | 16.59% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -2.24 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -2.24 |
Piotroski F-Score | 5 |